GlassScriptPhysician profile
Amanda J Wirth
NPI 1376612150
$6,302.32
in general payments reported to CMS, 2019-2025
44 companies · $682 in 2025
The $682 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $619 · 2021: $1,852 · 2022: $747 · 2023: $866 · 2024: $715 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,262.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,273.76 | 2021 | |
| Abbvie INC. | $1,226.02 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.02 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $349.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $343.75 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $328.66 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $280.87 | 2019-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $221.42 | 2019-2020 | |
| Glaxosmithkline, LLC. | $176.14 | 2019-2024 | Shingrix, Arexvy |
| Amgen INC. | $165.24 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $161.05 | 2019-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $156.56 | 2020-2025 | Belbuca |
| Bayer Healthcare Pharmaceuticals INC. | $125.78 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $96.21 | 2019-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Corcept Therapeutics | $81.76 | 2024 | Korlym |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wirth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.